Analyst Price Targets — KALA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| September 30, 2025 1:32 pm | — | Mizuho Securities | $1.50 | $1.81 | TheFly | Kala Bio downgraded to Neutral from Outperform at Mizuho |
| September 17, 2025 10:19 am | — | H.C. Wainwright | $35.00 | $17.47 | TheFly | Kala Pharmaceuticals price target raised to $35 from $12 at H.C. Wainwright |
| August 7, 2024 6:18 am | Yi Chen | H.C. Wainwright | $7.50 | $3.10 | TheFly | Kala Pharmaceuticals price target lowered to $15 from $18 at H.C. Wainwright |
| May 17, 2024 10:34 am | Yi Chen | H.C. Wainwright | $9.00 | $3.25 | TheFly | Kala Pharmaceuticals price target lowered to $18 from $21 at H.C. Wainwright |
| April 3, 2024 6:43 am | Yi Chen | H.C. Wainwright | $10.50 | $4.00 | StreetInsider | Kala Pharmaceuticals (KALA) PT Lowered to $21 at H.C. Wainwright |
Latest News for KALA
KALA BIO Announces Reverse Stock Split
ARLINGTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“KALA BIO” or the “Company”), today announced that it intends to effect a reverse stock split of its common stock, par value $0.001 per share (the “common stock”) at a ratio of 1 post-split share for every 50 pre-split shares.
Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine
ARLINGTON, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“KALA” or the “Company”) today celebrated the landmark Executive Order signed by U.S. President Donald J.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for KALA.
U.S. House Trading
No House trades found for KALA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.